M0 Prostate Cancer VL

AUA Castration-Resistant Prostate Cancer Guidelines - Interview with Michael Cookson

Details
(Length of Discussion: 10 min) Michael Cookson, MD, MMHC, talks with Alicia Morgans, MD on the newest developments in the AUA CRPC guidelines and how they have adapted with the latest results of the SPARTAN and PROSPER nmCRPC studies. The purpose of this guideline amendment is essentially to update current management of index patient 1: asymptomatic non-metastatic CRPC. Michael shares there is a n...

The Incredible Shrinking M0 CRPC - Phillip Koo

Details
(Length of Presentation: 12 min) Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient. His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He d...

The Implications of the SPARTAN Trial in the treatment of nmCRPC in Clinical Practice - Conversation with Eric Small

Details
(Length of Discussion: 23 min) Eric Small discusses (SPARTAN), the Study of Apalutamide in Men With Non-Metastatic Castration-Resistant Prostate Cancer with Alicia Morgans. He reviews the trial and the practical clinical practice questions that the data raises. He details the logic behind the development of the study and the unmet need for this patient population. Other key points discussed includ...

First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small

Details
(Length of Presentation: 23 min) The first presentation of a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), called SPARTAN is provided here. Eric Small presents the SPARTAN trial first data analysis including the background, methods, primary end points, time to metastasis, progress...

M0 CRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans

Details
(Length of Conversation: 24 min) Alicia Morgans and Charles Ryan discuss data that was presented at the ASCO GU 2018 meeting including two phase III trials, Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer ( SPARTAN ) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer ( PROSPER ) and the advances fo...

M0 CRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.

Details
(Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...

SPARTAN: A Study of Apalutamide in Men with M0 Castration-Resistant Prostate Cancer M0 CRPC) - Alan Bryce

Details
(Length of Presentation and Discussion: 9 minutes) Alan Bryce provides an overview of results from SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer - and the subsequent FDA approval of apalutamide for treatment of men with M0 castration resistant prostate cancer ( M0 CRPC). The presentation includes a review of the data on the primary and se...

Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small

Details
(Length of Discussion: 25 min) Professor Eric Small, MD talks with Dr. Neal Shore in a post ASCO GU interview on Dr. Eric Small’s plenary presentation on the phase three global SPARTAN trial. A landscape changing treatment for patients with non-metastatic castration resistant prostate cancer. The first drug approved by FDA to satisfy an unmet need for nmCRPC or m0 patients. Dr. Eric Small gives an...